EUVIMEDEUVIMED entdecken
Crossref

A comparison of two chemotherapy regimens in advanced, recurrent, or metastatic salivary gland carcinoma

Ahmad Ameri, Ainaz Sourati, Behnaz Behzadi, Mansour Lesan, Farzad Taghizadeh-Hesary

Indian Journal of Cancer · 2023

DOI: 10.4103/ijc.ijc_1226_20 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Cancer, 2023. Verfasst von Ahmad Ameri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Carcinoma, Salivary Gland Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of chemotherapy in locally advanced, recurrent, and metastatic salivary gland carcinomas (LA-R/M SGCs) is still undefined. We aimed to compare the efficacy of two chemotherapy regimens in LA-R/M SGC. Materials and Methods: This prospective study compared paclitaxel (Taxol) plus carboplatin (TC) versus cyclophosphamide, doxorubicin, plus cisplatin (CAP) regimen in terms of overall response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), and overall survival (OS).

Results

Between October 2011 and April 2019, 48 patients with LA-R/M SGCs were recruited. The ORRs of first-line TC and CAP regimens were 54.2% and 36.3%, respectively ( P = 0.57). The ORRs in recurrent and de novo metastatic patients were 50.0% and 37.5% for TC and CAP, respectively ( P = 0.26). The median PFS of TC and CAP arms were 10.2 and 11.9 months, respectively ( P = 0.91). In the subanalysis, patients with adenoid cystic carcinoma (ACC) had longer PFS in the TC arm (14.5 vs. 8.2 months, P = 0.03), irrespective of the tumor grade (low grade: 16.3 vs. 8.9 months, high grade: 11.7 vs. 4.5 months; P = 0.03). The median OS rates were 45.5 and 19.5 months for TC and CAP groups, respectively ( P = 0.71).

Conclusion

For patients with LA-R/M SGC, there was no significant difference between first-line TC and CAP in terms of ORR, PFS, and OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarcinomaSalivary Gland NeoplasmsHumansProspective StudiesDisease-Free SurvivalCisplatinCarboplatinPaclitaxelSalivary GlandsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Chemotherapylocally advancedmetastasisrecurrenceresponse ratesalivary gland carcinomasurvival

Substanzen

CisplatinCarboplatinPaclitaxel

Autor:innen und Institutionen

  • Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine; Radiation Oncology Department, Iran University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Ameri, A., Sourati, A., Behzadi, B., Lesan, M., & Taghizadeh-Hesary, F. (2023). A comparison of two chemotherapy regimens in advanced, recurrent, or metastatic salivary gland carcinoma. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_1226_20

Vancouver

Ameri A, Sourati A, Behzadi B, Lesan M, Taghizadeh-Hesary F. A comparison of two chemotherapy regimens in advanced, recurrent, or metastatic salivary gland carcinoma. Indian Journal of Cancer. 2023. doi:10.4103/ijc.ijc_1226_20

BibTeX
@article{Ameri2023,
  author = {Ameri, Ahmad and Sourati, Ainaz and Behzadi, Behnaz and Lesan, Mansour and Taghizadeh-Hesary, Farzad},
  title = {A comparison of two chemotherapy regimens in advanced, recurrent, or metastatic salivary gland carcinoma},
  journal = {Indian Journal of Cancer},
  year = {2023},
  doi = {10.4103/ijc.ijc_1226_20}
}
Kostenlos starten →